CNR Institutional Research Information System

DE FALCO, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 801
NA - Nord America 703
EU - Europa 208
SA - Sud America 166
Continente sconosciuto - Info sul continente non disponibili 75
AF - Africa 19
OC - Oceania 1
Totale 1.973
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 662
SG - Singapore 343
CN - Cina 176
BR - Brasile 122
VN - Vietnam 87
HK - Hong Kong 83
IT - Italia 65
FR - Francia 41
JP - Giappone 25
NL - Olanda 20
GB - Regno Unito 19
AR - Argentina 16
KR - Corea 16
CA - Canada 15
MX - Messico 14
BD - Bangladesh 13
DE - Germania 13
FI - Finlandia 11
CO - Colombia 10
EC - Ecuador 10
ID - Indonesia 10
IN - India 10
UA - Ucraina 7
IQ - Iraq 6
ZA - Sudafrica 6
AT - Austria 5
SE - Svezia 5
IE - Irlanda 4
TR - Turchia 4
VE - Venezuela 4
DZ - Algeria 3
ES - Italia 3
HN - Honduras 3
IL - Israele 3
NG - Nigeria 3
RU - Federazione Russa 3
AE - Emirati Arabi Uniti 2
BG - Bulgaria 2
CR - Costa Rica 2
CY - Cipro 2
EE - Estonia 2
HU - Ungheria 2
JM - Giamaica 2
LB - Libano 2
MY - Malesia 2
PH - Filippine 2
PK - Pakistan 2
PY - Paraguay 2
SA - Arabia Saudita 2
SC - Seychelles 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UZ - Uzbekistan 2
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
JO - Giordania 1
KE - Kenya 1
LC - Santa Lucia 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
OM - Oman 1
PE - Perù 1
PL - Polonia 1
PT - Portogallo 1
RO - Romania 1
TW - Taiwan 1
VG - Isole Vergini Britanniche 1
Totale 1.898
Salva come PNG Salva come JPEG
Città #
Santa Clara 203
Singapore 181
Hong Kong 82
San Jose 64
Beijing 56
Ashburn 50
Hefei 40
Lauterbourg 36
Los Angeles 34
Ho Chi Minh City 33
Tokyo 20
Hanoi 19
Seoul 16
São Paulo 11
Helsinki 10
Marigliano 10
Buffalo 9
New York 9
Rome 8
Chicago 6
Johannesburg 6
Washington 6
Brooklyn 5
Denver 5
London 5
Naples 5
Philadelphia 5
Stockholm 5
Avellino 4
Baghdad 4
Curitiba 4
Dallas 4
Florence 4
Haiphong 4
Lecce 4
Milan 4
Nuremberg 4
Orem 4
Quito 4
The Bronx 4
Acalanes Ridge 3
Boardman 3
Catania 3
Chennai 3
Dhaka 3
Falkenstein 3
Houston 3
Jacksonville 3
Manchester 3
Mexico City 3
Miami 3
Milwaukee 3
Montreal 3
Queens 3
Querétaro 3
Rio de Janeiro 3
San Francisco 3
Seattle 3
Toronto 3
Vienna 3
Amsterdam 2
Araranguá 2
Balikpapan 2
Bariri 2
Bengaluru 2
Bogotá 2
Boston 2
Brescia 2
Buenos Aires 2
Campinas 2
Cleveland 2
Dublin 2
Eagleville 2
Gainesville 2
Goiânia 2
Guayaquil 2
Kingston 2
La Crosse 2
Lagos 2
Las Vegas 2
Leesburg 2
Lima 2
Lithia Springs 2
Lomas de Zamora 2
Louisville 2
Manizales 2
Marília 2
Minamishinagawa 2
Moreno Valley 2
Newark 2
Nicosia 2
Ninh Bình 2
Niterói 2
Osaka 2
Osasco 2
Phoenix 2
Phủ Lý 2
Piscataway 2
Portland 2
Quảng Ninh 2
Totale 1.127
Salva come PNG Salva come JPEG
Nome #
N-Acetyl-L-Cysteine (NAC) Blunts Axitinib-Related Adverse Effects in Preclinical Models of Glioblastoma 84
The b-catenin Axis Integrates Multiple Signals Downstream From RET/PTC and Leads to Cell Proliferation. 75
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics 68
A new germline RET mutation apparently devoid of transforming activity serendipitously discovered in a patient with atrophic autoimmune thyroiditis and primary ovarian failure 63
The Role of Nutrients in Prevention, Treatment and Post-Coronavirus Disease-2019 (COVID-19) 62
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells 62
Targeted Cancer Therapy and Mechanisms of Resistance 61
Targeting the p90RSK/MDM2/p53 Pathway Is Effective in Blocking Tumors with Oncogenic Up-Regulation of the MAPK Pathway Such as Melanoma and Lung Cancer 61
Next-generation sequencing analysis of receptor-type tyrosine kinase genes in surgically resected colon cancer: Identification of gain-of-function mutations in the RET proto-oncogene 60
Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. 59
p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors 57
CD44 proteolysis increases CREB phosphorylation and sustains proliferation of thyroid cancer cells. 55
Effects of combined administration of rapamycin, tolvaptan and AEZ-131 on progression of polycystic disease in PCK rats. 54
XB130 mediates cancer cell proliferation and survival through multiple signaling events downstream of Akt. 53
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent Polypharmacology 52
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer 52
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. 51
A novel pathway of cell growth regulation mediated by a PLA2alpha-derived phosphoinositide metabolite 50
Cytosolic phospholipase A2 alpha regulates cell growth in RET/PTC-transformed thyroid cells 49
Calcium/calmodulin-dependent protein kinase II and its endogenous inhibitor ? in medullary thyroid cancer. 49
Calcium/calmodulin-dependent protein kinase II and ITS endogenous inhibitor a in medullary thyroid cancer 47
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. 46
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC 45
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells. 45
Glioblastoma: Overview of Proteomic Investigations and Biobank Approaches for the Development of a Multidisciplinary Translational Network 44
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells 43
BRAF is a therapeutic target in aggressive thyroid carcinoma. 42
Mitochondrial Localization and Regulation of BRAF(V600E) in Thyroid Cancer: A Clinically Used RAF Inhibitor Is Unable to Block the Mitochondrial Activities of BRAF(V600E) 41
RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase. 40
Targeting RET Kinase in Thyroid Cancer 39
The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma. 38
The β-Catenin axis integrates multiple signals downstream from RET/Papillary thyroid carcinoma leading to cell proliferation 37
Biochemical and molecular characterization of the novel BRAF V599Ins mutation detected in a classic papillary thyroid carcinoma 35
Ras-mediated apoptosis of PC CL 3 rat thyroid cells induced by RET/PTC oncogenes 32
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells 31
RAI(ShcC/N-Shc)-dependent recruitment of GAB 1 to RET oncoproteins potentiates PI 3-K signalling in thyroid tumors. 30
Molecular genetics of medullary thyroid carcinoma: The quest for novel therapeutic targets 29
Insights into the molecular function of the inactivating mutations of B-Raf involving the DFG motif 29
Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma 27
Functional expression of the CXCR4 chemokine receptor is induced by RET/PTC oncogenes and is a common event in human papillary thyroid carcinomas 27
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer 25
The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation. 24
Totale 1.973
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.773
article - articoli 6.773
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.546
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202411 0 0 0 0 0 0 0 0 2 0 9 0
2024/2025757 8 1 48 20 216 41 10 69 62 27 135 120
2025/2026975 31 86 75 151 188 72 144 38 60 80 29 21
2026/2027230 59 47 124 0 0 0 0 0 0 0 0 0
Totale 1.973